Highlights From ESMO Gastrointestinal Cancers Congress 2025 by Rasha Aboelhassan
The ESMO Gastrointestinal Cancers Congress 2025 is taking place from July 2-5 in Barcelona, Spain, with an online option available through a dedicated virtual platform. Organized by the European Society for Medical Oncology, this key event gathers leading experts, researchers, and healthcare professionals who are focused on advancing treatment and care for gastrointestinal cancers.
Attendees are experiencing groundbreaking presentations, multidisciplinary tumor boards, and lively discussions on the latest research, innovative therapies, and emerging technologies. The program covers a wide range of topics, including molecular prevention, precision therapy, and patient-centered approaches. In addition, there are plenty of networking opportunities for participants to connect with peers and share ideas.
Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared Highlights From ESMOGI25, on LinkedIn.
“Gerald Prager thanks for discussion oligometastatic disease in rectal cancer.
Should we begin with local control if patient is symptomatic?
- How to begin systemic therapy?
- Add targeted therapy?
- Chemotherapy only?
When should we do surgery? is there is any role for cDNA?
Great discussion.”
“The great debate.
Julio Garcia Aguilar and ESMOGI2025 panel day 2
Great discussion about which rectal cancer patient will be eligible for organ preservation?
How should begin treatment for this patient in the photo?
Especially when we know that this is a female 35 year old
In this photo, patient had induction with systemic therapy FOLFOX with reaching PR.
Great discussion”
“Veronique Vendrely
One of the best professional lecturers that I have ever attended about lower rectal cancer organ preservation.”
“How to define the strategies for managing HCC?
Should we change our rational for HCC clinical trials end points?
Totally agree for the need to change our view to PFS because not all types of progression is the same.
Thanks for your efforts all panellists who made a great efforts to help individuals treatment for each types of HCC patient profiles, as well as explained updated strategies of treatment.
And especially for you Maria Reig for the introduction of HCC session.”
“I really loved the approach that Servier symposium taken during ESMOGI2025
Thy walked with audiences and the case from first line and through maintenance therapy then second line and further lines of treatment in advanced colon /rectal cancer.
At the final survey, most of the audiences themselves, gave the recommendations of FTD/TPI for the patient”
“Paper discussion is a talent
I really enjoyed the discussion by Prof Lorenza Rimassa for TALENTACE phase 3 clinical trial today as well as CHECKMATE 9DW”
“Organ preservation in MSI-H colon cancer
Two different conclusions from two professional speakers.
The main points is that organ preservation need MDT
We need to choose suitable patients according to initial stage and adequate response assessment.
Some patient benefit from induction immunotherapy, to avoid major surgery not to preserve organs.”
More posts featuring ESMOGI2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023